Biomimetic Innovations

What Biomimetic Innovations does

Biomimetic Innovations is a medical device company that specializes in the development and commercialisation of synthetic biomaterial technology for tissue repair.

Name

Biomimetic Innovations

Legal name

Biomimetic Innovations Ltd.

Website

https://pbcbiomed.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Biomimetic Innovations is a medical device company that specializes in the development of synthetic biomaterial technology.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Synthetic bone void filler
• Injectable bone adhesive
• Orthopedic biomaterials
• Peri-articular fracture fixation
• Biomimetic medical devices

Headquarters

HQ city

Shannon

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing Revenue (Sanara MedTech): Biomimetic Innovations generates revenue through exclusive licensing agreements. Sanara MedTech invested €8 million for approximately 12.5% equity and exclusive U.S. marketing and distribution rights to OsStic. Additional milestone-based payments are included in the agreement.
2. Milestone Payments: Development milestone payments from Sanara MedTech as OsStic progresses toward commercialization, with committed up to EUR 8.0M for development milestones.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Biomimetic Innovations develops and commercializes OsStic™, a synthetic injectable structural bio-adhesive bone void filler designed for reduction, provisional fixation, and void filling of peri-articular fractures. The proprietary formula combines Calcium Phosphate, Calcium Silicate, and Phosphoserine to provide nanoscale bonding to bone and metal, adhesive stabilization, and biomimetic remodeling into natural bone. The company distributes its technology through an exclusive U.S. licensing agreement with Sanara MedTech.

Product overview

Biomimetic Innovations Ltd operates as an affiliate of PBC Biomed, specializing in the commercialization of OsStic™ technology. The company is focused on developing and commercializing a novel bone adhesive technology inspired by biology for both skeletal and soft tissue repair applications. OsStic™ is a synthetic injectable bone void filler designed to work with the body's natural healing process, providing adhesive stabilization of bone fragments, structural support for osteochondral and multi-fragmentary fractures, and an osteoconductive remodelling scaffold. The company was founded following a decade-long collaboration between GP Bio Ltd and PBC Biomed Ltd, combining deep expertise in biomaterials and bone repair.

Differentiator

Problem solved

Functional benefit

Brands

• OsStic: A structural, mechanically enhanced bio-adhesive for reduction, provisional fixation, or void filling of peri-articular fractures. Contains Calcium Phosphate, Calcium Silicate, and Phosphoserine. Received FDA Breakthrough Device Designation in January 2024.

Products and services

• OsStic™ Synthetic Bone Void Filler A structural, mechanically enhanced injectable bio-adhesive synthetic bone void filler for reduction, provisional fixation, and void filling of peri-articular fractures or defects. The formula combines Calcium Phosphate, Calcium Silicate, and Phosphoserine to create nanoscale bonding to bone and metal, mimicking the body's natural healing process and remodeling into natural bone over time. Targeted at trauma and orthopedic surgeons.

Quantifiable outcome

• FDA Breakthrough Device Designation received December 2023
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Sanara MedTech Inc.coreChannel Partner/ Reseller/ Distributor · 1 January 2025Exclusive license and distribution agreement announced January 2025. Sanara MedTech acquired exclusive U.S. marketing and distribution rights for OsStic and invested €8 million for approximately 12.5% equity in Biomimetic Innovations. The agreement includes milestone-based payments and a renewal option for the license.
• Leeds University Teaching HospitalcoreStrategic or Co-development PartnerClinical study site for first-in-human evaluation of OsStic in tibial plateau fractures. MHRA-approved clinical study led by Principal Investigator Professor Peter Giannoudis. Study approved March 2026 with completion expected by 2028.
• GP Bio LtdcoreStrategic or Co-development PartnerCo-founding partner of Biomimetic Innovations. The company was established following a decade-long collaboration between GP Bio Ltd and PBC Biomed combining expertise in biomaterials and bone repair.
• PBC Biomed LtdcoreStrategic or Co-development PartnerParent company and co-founding partner. Biomimetic Innovations operates as an affiliate of PBC Biomed, which provides design, development, and manufacturing capabilities. PBC Biomed's ISO 13485:2016 and ISO 9001:2015 certified facilities support product development.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Bonesupport: Swedish-listed orthopedic company specializing in injectable bone substitute products (e.g., CERAMENT) for trauma and bone infection. Directly comparable to OsStic as a synthetic injectable bone void filler targeting orthopedic fracture and defect management.
• Cerapedics: Private orthopedic company developing synthetically formulated peptide-enhanced bone graft substitutes (i-FACTOR) for spine and orthopedic applications. Comparable to OsStic as a specialized biomaterial-based bone graft / orthobiologic.
• Biocomposites: UK-based medical device company developing and manufacturing synthetic calcium-based bone graft substitutes (e.g., Stimulan, genex) for orthopedic infection, trauma, and bone defects. Closely comparable to OsStic in product category and indications.
• Kuros Biosciences: Swiss-listed orthopedic company developing synthetic bone graft substitutes (e.g., MagnetOs, Attrax) for spinal fusion and trauma. Comparable as a specialist orthobiologic with synthetic bone void filler / bone graft products.
• Xtant Medical: U.S.-listed orthopedic company focused on bone graft substitutes and spine biologics. Comparable to OsStic as a bone graft / orthobiologic commercial-stage specialist.

Emerging players

• Induce Biologics: Emerging orthopedic biologics company focused on bone regeneration and orthobiologic technologies. Comparable niche biomaterials focus to OsStic, though with portfolio orientation toward regenerative orthopedics.

Broad incumbents

• Orthofix Medical: Established global orthopedic and spine company with bone growth stimulation and biologics products. Comparable as a broad orthopedic incumbent with overlapping trauma and bone healing offerings.
• Stryker: Global orthopedic medical device leader with trauma, extremities, and orthobiologics product lines including bone graft substitutes. Comparable broad incumbent covering the same procedural call points as OsStic.
• Smith+Nephew: Global orthopedic and sports medicine company with bone graft substitute and regenerative products. Comparable broad incumbent serving the same trauma and orthopedic surgeon customers.
• Medtronic (Spine & Biologics): Global medical device leader with spinal biologics and bone graft substitute offerings marketed to spine and orthopedic surgeons. Comparable broad incumbent encompassing overlapping procedural categories where OsStic aims to expand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biomimetic-innovations-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomimetic Innovations